Can advanced diagnostic technologies reduce costs and improve outcomes by allowing earlier DAA treat
In current clinical practice, an accurate assessment of hepatic fibrosis is a vital factor for the initiation of Hepatitis C virus (HCV) treatment strategies using direct acting antivirals (DAAs). Typically, patients who are diagnosed with severe fibrosis (>F3) are covered by most payers (both public and private), while patients that exhibit little or no fibrosis are advised to defer DAA treatment and elect for a “watchful waiting” regimen. However, recent evidence suggests that beginning treatment at a METAVIR score of F2 or lower could help reduce overall DAA costs and improve treatment outcomes, as measured by sustained virologic response (SVR). In a December 2016 study by Bach and Zai
Rochester, MN, USA — Resoundant, Inc. is pleased to once again be exhibiting at the International Liver Congress™ (ILC), hosted by the European Association for the Study of the Liver (EASL), being held on April 19 — 23, 2017, at the RAI Exhibition and Convention Centre in Amsterdam, The Netherlands. "The International Liver Congress™ is an important scientific and clinical meeting," said Richard L. Ehman, MD, CEO of Resoundant, Inc, professor of Radiology and the Blanche R. & Richard J. Erlanger Professor of Medical Research at the Mayo Clinic. “Once again, we are honored to be part of the event.” Resoundant, Inc. will be exhibiting at Booth #184, where attendees can learn more about how
